2014年的合成代谢骨疗法：用于骨质疏松症的新型骨形成治疗方法。 - Suppr | 超能文献

相似文献

1

Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis.2014年的合成代谢骨疗法：用于骨质疏松症的新型骨形成治疗方法。

Nat Rev Endocrinol. 2015 Feb;11(2):69-70. doi: 10.1038/nrendo.2014.214. Epub 2014 Dec 9.

2

[Osteoanabolics and the forthcoming drugs for the treatment of osteoporosis].[骨合成代谢药物与即将上市的骨质疏松症治疗药物]

Reumatizam. 2014;61(2):95-9.

3

Mechanisms of anabolic therapies for osteoporosis.骨质疏松症的合成代谢治疗机制。

N Engl J Med. 2007 Aug 30;357(9):905-16. doi: 10.1056/NEJMra067395.

4

MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.内分泌疾病的管理：骨质疏松症的新型合成代谢治疗方法

Eur J Endocrinol. 2018 Feb;178(2):R33-R44. doi: 10.1530/EJE-17-0920. Epub 2017 Nov 7.

5

[Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].[骨质疏松症的治疗创新（抗硬化蛋白抗体和地诺单抗）]

Ann Endocrinol (Paris). 2011 Oct;72 Suppl 1:S15-22. doi: 10.1016/S0003-4266(11)70005-1.

6

[Update and perspectives of anabolic therapies for osteoporosis].[骨质疏松症合成代谢疗法的更新与展望]

Clin Calcium. 2012 Mar;22(3):327-33.

7

Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action.靶向抑制骨硬化蛋白治疗绝经后骨质疏松症：作用机制的批判性评估。

Eur J Pharmacol. 2018 May 5;826:39-47. doi: 10.1016/j.ejphar.2018.02.028. Epub 2018 Feb 22.

8

Two pioneering osteoporosis drugs finally approach approval.两种开创性的骨质疏松症药物终于接近获批。

Nat Rev Drug Discov. 2016 Jun 30;15(7):445-6. doi: 10.1038/nrd.2016.132.

9

Anabolic Therapy for the Treatment of Osteoporosis in Childhood.儿童骨质疏松症的合成代谢治疗。

Curr Osteoporos Rep. 2018 Jun;16(3):269-276. doi: 10.1007/s11914-018-0434-z.

10

Anabolic therapy in glucocorticoid-induced osteoporosis.糖皮质激素诱导性骨质疏松症的合成代谢疗法。

N Engl J Med. 2007 Nov 15;357(20):2084-6. doi: 10.1056/NEJMe0706770.

引用本文的文献

1

Comparison of unipedicular and bipedicular kyphoplasty for treating acute osteoporotic vertebral compression fractures in the lower lumbar spine: a retrospective study.单双侧入路椎体后凸成形术治疗下腰椎骨质疏松性椎体压缩骨折的比较：一项回顾性研究。

BMC Musculoskelet Disord. 2023 May 23;24(1):410. doi: 10.1186/s12891-023-06545-0.

2

A brief review and clinical evidences of teriparatide therapy for atypical femoral fractures associated with long-term bisphosphonate treatment.特立帕肽治疗与长期双膦酸盐治疗相关的非典型股骨骨折的简要综述及临床证据

Front Surg. 2023 Jan 6;9:1063170. doi: 10.3389/fsurg.2022.1063170. eCollection 2022.

3

本文引用的文献

1

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.一项关于抗硬化蛋白抗体布洛索单抗在绝经后低骨密度女性中的随机、双盲2期临床试验。

J Bone Miner Res. 2015 Feb;30(2):216-24. doi: 10.1002/jbmr.2351.

2

Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody.骨硬化蛋白抗体增加骨形成和骨量的组织水平机制。

J Bone Miner Res. 2014 Jun;29(6):1424-30. doi: 10.1002/jbmr.2152.

3

Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.